U.S. pharmaceutical giant McKesson Corp. is moving its headquarters from San Francisco to its existing office in Las Colinas, Texas, in April, according to the San Francisco Chronicle.
Pharmacy
Drug giant GlaxoSmithKline agreed to buy cancer treatment company Tesaro for about $5.1 billion including debt, according to CNBC.
A federal judge in Philadelphia has ruled that Bristol-Myers Squibb must face a whistle-blower lawsuit alleging the drugmaker knowingly underpaid rebates it owed to state Medicaid programs.
Healthcare leaders should expect changes as specialty drug spending continues to grow and health systems move to bring services closer to patients, among other trends in the new year, according to a new report from from the McKesson RxO team.
Although CVS Health's deal to buy Aetna for $69 billion closed Nov. 28, U.S. District Judge Richard Leon raised the prospect of not approving the deal during a routine legal process post-transaction, according to Reuters.
To minimize the debt burden it would assume if its $62 billion takeover of Shire is approved, Takeda Pharmaceuticals is considering a sale of up to $10 billion worth of assets, according to Nikkei Asian Review.
Twelve of the 19 largest pharmaceutical and biotech companies have at least one director serving on their board who simultaneously serves in a leadership position at a healthcare system, according to BioPharma Dive.
After a string of setbacks, Bayer AG will cut 12,000 jobs and shed several well-known brands in a bid to win back investors' trust, according to The Wall Street Journal.
The FDA is not only seeing an increased incidence of drug shortages, there's also been a jump in the intensity and duration of the shortages, according to Regulatory Focus.
As pharmacists expand their roles as providers, they'll need to not only help patients manage diseases, but prevent them.